Xenon Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $37.26
- Today's High:
- $37.85
- Open Price:
- $37.37
- 52W Low:
- $31.79
- 52W High:
- $43.75
- Prev. Close:
- $37.38
- Volume:
- 189850
Company Statistics
- Market Cap.:
- $2.40 billion
- Book Value:
- 10.146
- Revenue TTM:
- $132000
- Operating Margin TTM:
- -141010.61%
- Gross Profit TTM:
- $-96333000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -15.59%
- Return on Equity TTM:
- -22.86%
Company Profile
Xenon Pharmaceuticals Inc had its IPO on 2014-11-05 under the ticker symbol XENE.
The company operates in the Healthcare sector and Biotechnology industry. Xenon Pharmaceuticals Inc has a staff strength of 203 employees.
Stock update
Shares of Xenon Pharmaceuticals Inc opened at $37.37 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $37.26 - $37.85, and closed at $37.27.
This is a -0.29% slip from the previous day's closing price.
A total volume of 189,850 shares were traded at the close of the day’s session.
In the last one week, shares of Xenon Pharmaceuticals Inc have slipped by -6.19%.
Xenon Pharmaceuticals Inc's Key Ratios
Xenon Pharmaceuticals Inc has a market cap of $2.40 billion, indicating a price to book ratio of 3.2172 and a price to sales ratio of 181.4446.
In the last 12-months Xenon Pharmaceuticals Inc’s revenue was $132000 with a gross profit of $-96333000 and an EBITDA of $-184304992. The EBITDA ratio measures Xenon Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xenon Pharmaceuticals Inc’s operating margin was -141010.61% while its return on assets stood at -15.59% with a return of equity of -22.86%.
In Q2, Xenon Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Xenon Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.06
Its diluted EPS in the last 12-months stands at $-2.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.06. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xenon Pharmaceuticals Inc’s profitability.
Xenon Pharmaceuticals Inc stock is trading at a EV to sales ratio of 136.051 and a EV to EBITDA ratio of -16.4147. Its price to sales ratio in the trailing 12-months stood at 181.4446.
Xenon Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $684.90 million
- Total Liabilities
- $28.16 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $2.13 million
- Dividend Payout Ratio
- 0%
Xenon Pharmaceuticals Inc ended 2024 with $684.90 million in total assets and $0 in total liabilities. Its intangible assets were valued at $684.90 million while shareholder equity stood at $646.46 million.
Xenon Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $28.16 million in other current liabilities, 1083008000.00 in common stock, $-571935000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $64.55 million and cash and short-term investments were $539.60 million. The company’s total short-term debt was $1,223,000 while long-term debt stood at $0.
Xenon Pharmaceuticals Inc’s total current assets stands at $544.62 million while long-term investments were $112.59 million and short-term investments were $475.05 million. Its net receivables were $2.12 million compared to accounts payable of $12.03 million and inventory worth $-2123000.00.
In 2024, Xenon Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $2.13 million.
Comparatively, Xenon Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $37.27
- 52-Week High
- $43.75
- 52-Week Low
- $31.79
- Analyst Target Price
- $52.64
Xenon Pharmaceuticals Inc stock is currently trading at $37.27 per share. It touched a 52-week high of $43.75 and a 52-week low of $43.75. Analysts tracking the stock have a 12-month average target price of $52.64.
Its 50-day moving average was $37.81 and 200-day moving average was $38.13 The short ratio stood at 7.79 indicating a short percent outstanding of 0%.
Around 65.4% of the company’s stock are held by insiders while 9459.5% are held by institutions.
Frequently Asked Questions About Xenon Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.